X0306 4 2017-02-24 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001389147 DILLY STEPHEN GEORGE AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 1 1 0 0 See Remarks Common Stock, $0.0001 par value 715308 D Common Stock, $0.0001 par value 51403 I By GRAT 1 Common Stock, $0.0001 par value 14447 I By GRAT 2 Common Stock, $0.0001 par value 51403 I By Wife's GRAT 1 Common Stock, $0.0001 par value 14447 I By Wife's GRAT 2 Stock Option (right to buy) 19.63 2017-02-24 4 A 0 240000 0.00 A 2027-02-24 Common Stock 240000 240000 D A portion of these shares is subject to a right of repurchase held by the Issuer These shares are held by Stephen G. Dilly, as Trustee of The Stephen G. Dilly 2015 Grantor Retained Annuity Trust dated June 23, 2015 (the "First Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the First Dilly Trust. These shares are held by Stephen G. Dilly, Trustee, The Stephen G. Dilly 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Dilly Trust"). Dr. Dilly has sole voting, investment and dispositive power over the shares held by the Second Dilly Trust. These shares are held by Edwina Lynette Mullens, as Trustee of The Edwina Lynette Mullens 2015 Grantor Retained Annuity Trust dated June 23, 2015 (the "First Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the First Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the First Mullens Trust. These shares are held by Edwina Lynette Mullens, Trustee, The Edwina Lynette Mullens 2016 Grantor Retained Annuity Trust DTD August 12, 2016 (the "Second Mullens Trust"). Ms. Mullens has sole voting, investment and dispositive power over the shares held by the Second Mullens Trust. Dr. Dilly disclaims beneficial ownership of the shares held by the Second Mullens Trust. The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. President and Chief Executive Officer /s/ Warren L. DeSouza, as Attorney in Fact for Stephen G. Dilly 2017-02-24